Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 26.
doi: 10.1097/HEP.0000000000001284. Online ahead of print.

Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC

Affiliations

Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC

Tomohiko Taniai et al. Hepatology. .

Abstract

Background and aims: Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled us to clarify gene regulatory networks and immune cell compositions. In this study, the integration of large-scale bulk and single-cell datasets refined HCC classification and shed light on the characteristics of its aggressive subtype.

Approach and results: Single-cell analysis of 228,564 live cells from 6 scRNA-seq datasets identified 5 major clusters of HCC cells with high mitotic activity (cluster 1), activated Wnt/β-catenin signaling (cluster 2), elevated glycolysis (cluster 3), and lipogenesis (clusters 4 and 5). Aggressive HCC subtype defined in bulk RNA-seq analysis of 691 tumor samples comprised a combination of cluster 1 with clusters 3, 4, or 5. Gene regulatory network analysis and gene set enrichment analysis highlighted the essential roles of p53 and MYC in aggressive HCC/cluster 1, and cell composition analysis elucidated T cell depletion as an immune resistance mechanism. In a syngeneic mouse model, Trp53 knockout and MYC overexpression caused high mitotic, tumorigenic, and metastatic phenotypes, characterized by a macrotrabecular pattern, vascular encapsulation, and T cell exclusion. Angiogenesis inhibition disrupted macrotrabecular/vascular encapsulation formation, resulting in T cell recruitment, and its combination with immune checkpoint blockade achieved remission.

Conclusions: Single-cell analysis has deepened our understanding of the molecular mechanism and tumor microenvironment in aggressive HCC. The combination of targeting tumor vasculature and blocking immune checkpoints represents a promising therapeutic strategy for this subtype.

Keywords: HCC; comprehensive bulk and single-cell analyses; immunosuppressive microenvironment; macrotrabecular pattern; subtype-specific therapy; syngeneic model; vessels encapsulating tumor clusters.

PubMed Disclaimer

References

    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
    1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681–693.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
    1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.

LinkOut - more resources